Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICRO-K 10 vs CALCIUM GLUCONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium is the major intracellular cation; it is essential for the maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium chloride is absorbed from the gastrointestinal tract and distributes throughout the body. The microencapsulated formulation allows for gradual release of potassium, minimizing gastrointestinal irritation.
Calcium gluconate dissociates to provide calcium ions, which are essential for nerve impulse transmission, muscle contraction, cardiac function, and blood coagulation. It acts as a mineral electrolyte replenisher.
Treatment of hypokalemia,Prevention of hypokalemia in patients receiving digitals or diuretics for congestive heart failure, hepatic cirrhosis, or nephrotic syndrome,Correction of hypokalemia in patients with hypertension on long-term diuretic therapy
Emergency treatment of hypocalcemia,Cardiac resuscitation (e.g., hyperkalemia, calcium channel blocker overdose, beta-blocker overdose),Treatment of hypermagnesemia,Treatment of acute symptomatic hypocalcemic tetany,Off-label: Prevention of hypocalcemia during massive blood transfusion, adjunctive treatment of lead poisoning (calcium EDTA), and treatment of fluoride poisoning
10 m Eq (2 capsules) orally once daily, or 20 m Eq (2 capsules) twice daily, or as directed by physician. Maximum 100 m Eq/day.
Intravenous: 1-2 grams (10-20 m L of 10% solution) administered slowly over 5-10 minutes. May repeat based on serum calcium levels.
Not applicable; potassium is not cleared by first-order kinetics. Whole-body potassium turnover half-life is approximately 30 days, but this is not clinically relevant for supplementation.
Rapid distribution half-life ~5-10 min; terminal half-life 3-6 hours due to redistribution and renal excretion; clinically, effect duration is short (1-2 hours) due to rapid redistribution into bone and other tissues.
Potassium is not metabolized. Approximately 90% of ingested potassium is excreted in the urine, with the remainder excreted in feces and sweat. There is no hepatic metabolism.
Calcium gluconate is not metabolized. It dissociates to release calcium ions, which are distributed in the body and excreted primarily via the kidneys. The gluconate moiety is metabolized via the Krebs cycle.
Primarily renal: 90% of absorbed potassium is excreted in urine as potassium ions; 10% eliminated in feces via biliary and intestinal secretion.
Primarily renal (calcium is filtered and reabsorbed); negligible biliary/fecal. >98% of body calcium is in bone; excretion is complex and homeostatically regulated.
0% bound to serum proteins; free ion in serum.
Approximately 45% bound to albumin; remaining free ionized calcium is the active form.
Total body water: 0.5 L/kg; distributes primarily intracellularly (98% of body potassium is intracellular), but Vd is not a clinically relevant parameter for potassium.
0.6-1.0 L/kg (distributes into extracellular fluid and bone; increases with bone turnover).
Oral (microencapsulated): 90-100% relative to intravenous; absorption is nearly complete via the gastrointestinal tract.
IV: 100%; IM: poor and erratic (not recommended); oral: ~20-30% (limited by absorption and binding, not used for urgent hypocalcemia).
GFR >50 m L/min: no adjustment. GFR 10-50 m L/min: reduce dose by 50% or use with caution. GFR <10 m L/min: contraindicated or use with extreme caution.
No specific dose adjustment for renal impairment; however, caution in severe renal failure (GFR <30 m L/min) due to risk of hypercalcemia. Monitor serum calcium closely.
No specific Child-Pugh based modifications; use with caution in severe hepatic impairment due to risk of hyperkalemia.
No adjustment required for hepatic impairment.
Children: 1-2 m Eq/kg/day in divided doses, not to exceed 20 m Eq per dose or 100 m Eq/day. Minimum dosing weight not specified; safety and efficacy not established in premature infants.
Neonates and infants: 100-200 mg/kg/dose (1-2 m L/kg of 10% solution) IV slowly, maximum 2 g; children: 1-2 g/dose IV, maximum 2 g. Dilute to 50 mg/m L (5% solution) for IV administration.
Elderly: start with lower doses (e.g., 10 m Eq once daily) due to age-related renal function decline; monitor serum potassium and renal function frequently.
Start at lower end of dosing range (e.g., 1 gram IV) due to increased risk of hypercalcemia and potential underlying renal insufficiency. Monitor calcium levels and cardiac function.
None
No FDA black box warning.
Hyperkalemia risk; use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia,Gastrointestinal irritation and ulceration; do not crush or chew tablets,May increase serum potassium levels in patients with adrenal insufficiency or diabetes,Use caution with potassium-sparing diuretics or ACE inhibitors
Risk of hypercalcemia; monitor serum calcium levels closely during therapy.,Risk of cardiac arrhythmias, especially if administered too rapidly or in patients receiving digoxin.,Avoid extravasation; may cause severe tissue necrosis (treat with hyaluronidase).,Use caution in renal impairment, sarcoidosis, or history of renal calculi.,Concomitant use with thiazide diuretics may increase risk of hypercalcemia.
Severe renal impairment with oliguria or azotemia,Addison's disease,Acute dehydration,Heat cramps,Hyperkalemia from any cause,Concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride)
Hypercalcemia,Severe renal failure (relative, use with caution),Patients with ventricular fibrillation (use during cardiopulmonary resuscitation may be indicated),Digoxin toxicity (relative; may exacerbate arrhythmias, use with extreme caution)
Avoid high-potassium foods (e.g., bananas, oranges, tomatoes, potatoes, salt substitutes) unless directed otherwise; intake may need to be restricted or monitored.
Avoid high-calcium foods (dairy, fortified cereals) if hypercalcemia is a concern; oxalate-rich foods (spinach, rhubarb) may reduce absorption; do not take within 2 hours of iron or tetracycline antibiotics.
Potassium chloride is not associated with fetal malformations. In all trimesters, excessive potassium intake can cause maternal hyperkalemia, which may lead to fetal arrhythmias or adverse outcomes. Recommended intakes are safe.
FDA Pregnancy Category C. First trimester: No well-controlled human studies; animal studies not available. Second/third trimesters: Calcium gluconate is a physiologic electrolyte; deficiency may cause fetal skeletal abnormalities, but supplementation at recommended doses is unlikely to increase risk of major malformations. High doses may cause maternal hypercalcemia; risk of fetal hypoparathyroidism, tetany, and seizures if maternal calcium acutely increased. No known teratogenicity.
Potassium is a normal constituent of breast milk with an M/P ratio of approximately 0.1-0.2. Supplemental potassium is not expected to cause adverse effects in nursing infants at usual maternal doses.
Excreted into breast milk; M/P ratio approximately 0.5. Considered compatible with breastfeeding in usual maternal doses. Monitor infant for signs of hypercalcemia if maternal doses are high.
No specific dose adjustment required for pregnancy. However, increased plasma volume and renal blood flow during pregnancy may lower serum potassium, potentially requiring higher doses for hypokalemia treatment. Individualize based on serum potassium monitoring.
Pregnancy-induced physiologic changes (increased plasma volume, increased GFR, placental calcium transfer) may lower maternal calcium levels; monitor and adjust dose as needed to maintain normal serum calcium. Intravenous doses typically require similar mg/kg dosing as non-pregnant; oral dosing may require a slight increase (10-20%) to compensate for increased demands and excretion. No standardized adjustment; individualized based on serum calcium levels.
Micro-K 10 (potassium chloride extended-release) is used for hypokalemia. Avoid in severe renal impairment (Cr Cl <30 m L/min) due to risk of hyperkalemia. Do not crush or chew capsules; administer with food to reduce GI irritation. Monitoring serum potassium levels is essential, especially in patients on digoxin or diuretics. Use with caution in patients with significant heart block or metabolic acidosis.
Administer via slow IV push (1-2 m L/min) to avoid cardiac arrest; monitor ECG during infusion; do not mix with bicarbonate or phosphate solutions; extravasation causes tissue necrosis; use with caution in digitalis toxicity.
Take this medication exactly as prescribed, usually once daily with food.,Do not crush, chew, or open the capsule; swallow whole.,Do not use salt substitutes or potassium supplements unless instructed by your doctor.,Seek medical attention if you experience muscle weakness, irregular heartbeat, or signs of GI obstruction (severe stomach pain, vomiting, or black stools).,Tell your doctor about all medications, especially diuretics or ACE inhibitors.
Report any pain, redness, or swelling at injection site immediately,Avoid taking calcium supplements or antacids containing calcium without consulting your doctor,Inform about any heart conditions, especially irregular heartbeat,May cause dizziness or fainting if infused too quickly
No interactions on record
"Calcium gluconate provides exogenous calcium, which can counteract the calcium channel blocking effect of nimodipine. This reduces nimodipine's ability to inhibit calcium influx into vascular smooth muscle cells, potentially decreasing its antihypertensive and vasodilatory efficacy. Clinically, coadministration may lead to reduced nimodipine effectiveness in preventing cerebral vasospasm after subarachnoid hemorrhage."
"Sodium glycerophosphate, an organic phosphate source, can chelate calcium ions in the gastrointestinal tract, forming insoluble calcium phosphate complexes. This reduces the absorption of orally administered calcium gluconate, leading to lower serum calcium concentrations. Clinically, this may result in diminished efficacy of calcium supplementation, potentially exacerbating hypocalcemia in susceptible patients."
"Calcium gluconate chelates deferiprone in the gastrointestinal tract, forming a non-absorbable complex that reduces deferiprone's bioavailability. This results in decreased serum concentrations and diminished therapeutic efficacy of deferiprone, potentially leading to inadequate chelation of iron in patients with iron overload. Clinically, patients may experience suboptimal reduction of serum ferritin and increased risk of iron-related organ damage."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICRO-K 10 vs CALCIUM GLUCONATE, answered by our medical review team.
MICRO-K 10 is a Electrolyte Supplement (Potassium) that works by Potassium is the major intracellular cation; it is essential for the maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium chloride is absorbed from the gastrointestinal tract and distributes throughout the body. The microencapsulated formulation allows for gradual release of potassium, minimizing gastrointestinal irritation.. CALCIUM GLUCONATE is a Electrolyte Supplement that works by Calcium gluconate dissociates to provide calcium ions, which are essential for nerve impulse transmission, muscle contraction, cardiac function, and blood coagulation. It acts as a mineral electrolyte replenisher.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICRO-K 10 and CALCIUM GLUCONATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICRO-K 10 is: 10 m Eq (2 capsules) orally once daily, or 20 m Eq (2 capsules) twice daily, or as directed by physician. Maximum 100 m Eq/day.. The standard adult dose of CALCIUM GLUCONATE is: Intravenous: 1-2 grams (10-20 m L of 10% solution) administered slowly over 5-10 minutes. May repeat based on serum calcium levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICRO-K 10 and CALCIUM GLUCONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICRO-K 10 is classified as Category C. Potassium chloride is not associated with fetal malformations. In all trimesters, excessive potassium intake can cause maternal hyperkalemia, which may lead to fetal arrhythmias or. CALCIUM GLUCONATE is classified as Category C. FDA Pregnancy Category C. First trimester: No well-controlled human studies; animal studies not available. Second/third trimesters: Calcium gluconate is a physiologic electrolyte; . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.